Connection

Daniel Judge to Arrhythmogenic Right Ventricular Dysplasia

This is a "connection" page, showing publications Daniel Judge has written about Arrhythmogenic Right Ventricular Dysplasia.
  1. Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovasc Res. 2017 01; 113(1):102-111.
    View in: PubMed
    Score: 0.562
  2. Absence of a Primary Role for SCN10A Mutations in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. J Cardiovasc Transl Res. 2016 Feb; 9(1):87-9.
    View in: PubMed
    Score: 0.525
  3. Further evidence of harm from exercise in ARVD/C. J Am Coll Cardiol. 2015 Apr 14; 65(14):1451-3.
    View in: PubMed
    Score: 0.499
  4. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: a family affair. Circulation. 2011 Jun 14; 123(23):2661-3.
    View in: PubMed
    Score: 0.383
  5. Shared desmosome gene findings in early and late onset arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Transl Res. 2010 Dec; 3(6):663-73.
    View in: PubMed
    Score: 0.364
  6. Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet. 2009 Oct; 2(5):428-35.
    View in: PubMed
    Score: 0.332
  7. Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat Clin Pract Cardiovasc Med. 2008 May; 5(5):258-67.
    View in: PubMed
    Score: 0.306
  8. Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2. Hum Mutat. 2006 Nov; 27(11):1157.
    View in: PubMed
    Score: 0.278
  9. Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2006 Oct 03; 48(7):1416-24.
    View in: PubMed
    Score: 0.275
  10. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation. 2006 Apr 04; 113(13):1641-9.
    View in: PubMed
    Score: 0.266
  11. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2022 08 21; 43(32):e1-e9.
    View in: PubMed
    Score: 0.208
  12. International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework. Circ Genom Precis Med. 2021 06; 14(3):e003273.
    View in: PubMed
    Score: 0.189
  13. Cadherin 2-Related Arrhythmogenic Cardiomyopathy: Prevalence and Clinical Features. Circ Genom Precis Med. 2021 04; 14(2):e003097.
    View in: PubMed
    Score: 0.187
  14. Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational Collaboration. Circ Arrhythm Electrophysiol. 2021 01; 14(1):e008509.
    View in: PubMed
    Score: 0.185
  15. Influence of Panel Selection on Yield of Clinically Useful Variants in Arrhythmogenic Right Ventricular Cardiomyopathy Families. Circ Genom Precis Med. 2020 10; 13(5):548-550.
    View in: PubMed
    Score: 0.182
  16. Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Heart Assoc. 2020 02 04; 9(3):e013695.
    View in: PubMed
    Score: 0.174
  17. FLNC truncations cause arrhythmogenic right ventricular cardiomyopathy. J Med Genet. 2020 04; 57(4):254-257.
    View in: PubMed
    Score: 0.173
  18. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm. 2019 11; 16(11):e373-e407.
    View in: PubMed
    Score: 0.171
  19. Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. Circ Genom Precis Med. 2019 08; 12(8):e002467.
    View in: PubMed
    Score: 0.168
  20. Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. J Clin Invest. 2019 07 02; 129(8):3171-3184.
    View in: PubMed
    Score: 0.167
  21. Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. Eur J Heart Fail. 2019 08; 21(8):955-964.
    View in: PubMed
    Score: 0.167
  22. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2019 06 14; 40(23):1850-1858.
    View in: PubMed
    Score: 0.166
  23. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019 11; 16(11):e301-e372.
    View in: PubMed
    Score: 0.165
  24. No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. PLoS One. 2018; 13(8):e0203078.
    View in: PubMed
    Score: 0.158
  25. Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy: Case Studies and Proposal for Clinical Surveillance. Circ Genom Precis Med. 2018 07; 11(7):e002237.
    View in: PubMed
    Score: 0.156
  26. Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). J Cardiovasc Electrophysiol. 2018 07; 29(7):1004-1009.
    View in: PubMed
    Score: 0.155
  27. Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circ Arrhythm Electrophysiol. 2018 02; 11(2):e005593.
    View in: PubMed
    Score: 0.152
  28. Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circ Heart Fail. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.147
  29. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications. J Am Heart Assoc. 2017 Jun 06; 6(6).
    View in: PubMed
    Score: 0.145
  30. Comparison of Features of Fatal Versus Nonfatal Cardiac Arrest in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Am J Cardiol. 2017 07 01; 120(1):111-117.
    View in: PubMed
    Score: 0.143
  31. Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. JAMA Cardiol. 2017 03 01; 2(3):293-302.
    View in: PubMed
    Score: 0.142
  32. Cardiac phenotype and long-term prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with late presentation. Heart Rhythm. 2017 06; 14(6):883-891.
    View in: PubMed
    Score: 0.142
  33. Characterizing the Molecular Pathology of Arrhythmogenic Cardiomyopathy in Patient Buccal Mucosa Cells. Circ Arrhythm Electrophysiol. 2016 Feb; 9(2):e003688.
    View in: PubMed
    Score: 0.132
  34. Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart. 2016 02 15; 102(4):303-12.
    View in: PubMed
    Score: 0.131
  35. Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm. 2016 Jan; 13(1):199-207.
    View in: PubMed
    Score: 0.128
  36. Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Eur Heart J. 2016 Mar 01; 37(9):755-63.
    View in: PubMed
    Score: 0.128
  37. Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet. 2015 Jun; 8(3):437-46.
    View in: PubMed
    Score: 0.124
  38. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015 Apr 07; 36(14):847-55.
    View in: PubMed
    Score: 0.123
  39. Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2015 Apr; 12(4):716-25.
    View in: PubMed
    Score: 0.122
  40. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc. 2014 Dec; 3(6):e001471.
    View in: PubMed
    Score: 0.122
  41. Yield of serial evaluation in at-risk family members of patients with ARVD/C. J Am Coll Cardiol. 2014 Jul 22; 64(3):293-301.
    View in: PubMed
    Score: 0.119
  42. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol. 2014 Apr; 7(2):230-6.
    View in: PubMed
    Score: 0.115
  43. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2013 Nov; 10(11):1661-8.
    View in: PubMed
    Score: 0.111
  44. Mutation-positive arrhythmogenic right ventricular dysplasia/cardiomyopathy: the triangle of dysplasia displaced. J Cardiovasc Electrophysiol. 2013 Dec; 24(12):1311-20.
    View in: PubMed
    Score: 0.111
  45. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013 Oct 01; 62(14):1290-1297.
    View in: PubMed
    Score: 0.111
  46. Malignant arrhythmogenic right ventricular dysplasia/cardiomyopathy with a normal 12-lead electrocardiogram: a rare but underrecognized clinical entity. Heart Rhythm. 2013 Oct; 10(10):1484-91.
    View in: PubMed
    Score: 0.110
  47. Exercise testing in asymptomatic gene carriers exposes a latent electrical substrate of arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2013 Nov 05; 62(19):1772-9.
    View in: PubMed
    Score: 0.110
  48. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013 Nov 05; 62(19):1761-9.
    View in: PubMed
    Score: 0.110
  49. Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. Circ Arrhythm Electrophysiol. 2013 Jun; 6(3):569-78.
    View in: PubMed
    Score: 0.109
  50. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012 Nov; 14(11):1199-207.
    View in: PubMed
    Score: 0.103
  51. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2012 Jun 01; 5(3):499-505.
    View in: PubMed
    Score: 0.101
  52. Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2012 Jun; 9(6):961-7.
    View in: PubMed
    Score: 0.100
  53. Cardiac transplantation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2012 Jan 17; 59(3):289-90.
    View in: PubMed
    Score: 0.100
  54. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011 Sep 27; 58(14):1485-96.
    View in: PubMed
    Score: 0.098
  55. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J Am Coll Cardiol. 2011 Jun 07; 57(23):2317-27.
    View in: PubMed
    Score: 0.096
  56. Reader- and instrument-dependent variability in the electrocardiographic assessment of arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol. 2011 May; 22(5):561-8.
    View in: PubMed
    Score: 0.092
  57. Morphologic variants of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy a genetics-magnetic resonance imaging correlation study. J Am Coll Cardiol. 2009 Apr 14; 53(15):1289-99.
    View in: PubMed
    Score: 0.082
  58. Prolonged RV endocardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2009 Jun; 6(6):769-75.
    View in: PubMed
    Score: 0.082
  59. Genetic evaluation of familial cardiomyopathy. J Cardiovasc Transl Res. 2008 Jun; 1(2):144-54.
    View in: PubMed
    Score: 0.077
  60. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007 Jul 31; 50(5):432-40.
    View in: PubMed
    Score: 0.073
  61. Use of a coronary sinus lead and biventricular ICD to correct a sensing abnormality in a patient with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol. 2006 Mar; 17(3):317-20.
    View in: PubMed
    Score: 0.066
  62. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005 Dec 20; 112(25):3823-32.
    View in: PubMed
    Score: 0.065
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.